SCIENCE OF
POSSIBILITY
At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.
Vertex announces that the U.S. FDA has lifted the clinical hold on the Phase 1/2 clinical trial for the potential treatment of type 1 diabetes
Vertex and CRISPR Tx present new data at EHA 2022 on investigational gene-edited therapy for the treatment of sickle cell...
Our investigational medicine for the potential treatment of APOL1-mediated kidney disease receives two regulatory designations
Vertex presents new data on Phase 1/2 clinical trial for type 1 diabetes at American Diabetes Association Scientific Sessions Conference
View our 2021 Corporate Responsibility Report
Working at Vertex
Working at Vertex
Our company is built on an inclusive culture that brings together the best and brightest in every field striving for one goal: to improve the lives of people with serious diseases.
Featured stories
Our commitment to inclusion, diversity and equity (ID&E) is longstanding and achieving our ambition takes collective action and shared ownership. Learn more about our approach from Vice President of Talent and ID&E Diana Cruz Solash.
Incredible talent and cross-functional collaboration. All that and more with Vertex’s type 1 diabetes team. Meet a few of the team members who are making a difference.
Our commitment to inclusion, diversity and equity (ID&E) is longstanding and achieving our ambition takes collective action and shared ownership. Learn more about our approach from Vice President of Talent and ID&E Diana Cruz Solash.
Incredible talent and cross-functional collaboration. All that and more with Vertex’s type 1 diabetes team. Meet a few of the team members who are making a difference.
